Cargando…

Biologic Treatments of Psoriasis: An Update for the Clinician

The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enha...

Descripción completa

Detalles Bibliográficos
Autores principales: Brownstone, Nicholas D, Hong, Julie, Mosca, Megan, Hadeler, Edward, Liao, Wilson, Bhutani, Tina, Koo, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896737/
https://www.ncbi.nlm.nih.gov/pubmed/33623366
http://dx.doi.org/10.2147/BTT.S252578
_version_ 1783653600269959168
author Brownstone, Nicholas D
Hong, Julie
Mosca, Megan
Hadeler, Edward
Liao, Wilson
Bhutani, Tina
Koo, John
author_facet Brownstone, Nicholas D
Hong, Julie
Mosca, Megan
Hadeler, Edward
Liao, Wilson
Bhutani, Tina
Koo, John
author_sort Brownstone, Nicholas D
collection PubMed
description The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enhanced. However, the fact that there are so many available options has also caused confusion for providers. Therefore, this manuscript deliberately focuses on the most clinically useful facts (such as efficacy and safety data) about each and every FDA approved biologic agent (including pipeline agents) for psoriasis. Moreover, among the clinically relevant facts, this manuscript purposely emphasizes the unique merits and demerits of each agent to make it easier for the provider to select which one of these many options is the best for the particular patient on hand. The goal of this manuscript is to aid the busy practicing dermatologist in becoming more adept at using these agents with the ultimate aim of improving patient care.
format Online
Article
Text
id pubmed-7896737
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78967372021-02-22 Biologic Treatments of Psoriasis: An Update for the Clinician Brownstone, Nicholas D Hong, Julie Mosca, Megan Hadeler, Edward Liao, Wilson Bhutani, Tina Koo, John Biologics Review The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enhanced. However, the fact that there are so many available options has also caused confusion for providers. Therefore, this manuscript deliberately focuses on the most clinically useful facts (such as efficacy and safety data) about each and every FDA approved biologic agent (including pipeline agents) for psoriasis. Moreover, among the clinically relevant facts, this manuscript purposely emphasizes the unique merits and demerits of each agent to make it easier for the provider to select which one of these many options is the best for the particular patient on hand. The goal of this manuscript is to aid the busy practicing dermatologist in becoming more adept at using these agents with the ultimate aim of improving patient care. Dove 2021-02-16 /pmc/articles/PMC7896737/ /pubmed/33623366 http://dx.doi.org/10.2147/BTT.S252578 Text en © 2021 Brownstone et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Brownstone, Nicholas D
Hong, Julie
Mosca, Megan
Hadeler, Edward
Liao, Wilson
Bhutani, Tina
Koo, John
Biologic Treatments of Psoriasis: An Update for the Clinician
title Biologic Treatments of Psoriasis: An Update for the Clinician
title_full Biologic Treatments of Psoriasis: An Update for the Clinician
title_fullStr Biologic Treatments of Psoriasis: An Update for the Clinician
title_full_unstemmed Biologic Treatments of Psoriasis: An Update for the Clinician
title_short Biologic Treatments of Psoriasis: An Update for the Clinician
title_sort biologic treatments of psoriasis: an update for the clinician
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896737/
https://www.ncbi.nlm.nih.gov/pubmed/33623366
http://dx.doi.org/10.2147/BTT.S252578
work_keys_str_mv AT brownstonenicholasd biologictreatmentsofpsoriasisanupdatefortheclinician
AT hongjulie biologictreatmentsofpsoriasisanupdatefortheclinician
AT moscamegan biologictreatmentsofpsoriasisanupdatefortheclinician
AT hadeleredward biologictreatmentsofpsoriasisanupdatefortheclinician
AT liaowilson biologictreatmentsofpsoriasisanupdatefortheclinician
AT bhutanitina biologictreatmentsofpsoriasisanupdatefortheclinician
AT koojohn biologictreatmentsofpsoriasisanupdatefortheclinician